{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"AURORAS-1","nct_id":"NCT06983743","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=auroras-1-nct06983743. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AURORAS-1","arms":[{"description":"Escalating doses of ERAS-0015 administered orally.","label":"ERAS-0015 Monotherapy Dose Optimization.","type":"EXPERIMENTAL"},{"description":"ERAS-0015 administered orally with another investigational agent.","label":"ERAS-0015 Combination Dose Optimization","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"conditions":["Metastatic Solid Tumors"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ERAS-0015","otherNames":[],"type":"DRUG"},{"name":"ERAS-0015 in combination","otherNames":["pembrolizumab","KEYTRUDA ®","panitumumab","Vectibix","gemcitabine","Gemzar","nab-paclitaxel","Abraxane"],"type":"DRUG"}],"last_update":"2026-11-06","lead_sponsor":"Erasca, Inc.","official_title":"A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-05-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose Limiting Toxicities (DLT)","timeFrame":"Study Day 1 up to Day 21"},{"measure":"Maximum tolerated dose (MTD)","timeFrame":"Study Day 1 up to Day 21"},{"measure":"Recommended dose for expansion (RDE)","timeFrame":"Study Day 1 up to Day 21"},{"measure":"Adverse Events","timeFrame":"Study Day 1 up to Day 21"},{"measure":"Plasma concentration (Cmax)","timeFrame":"Study Day 1 up to 65"},{"measure":"Time to achieve Cmax (Tmax)","timeFrame":"Study Day 1 up to 65"},{"measure":"Area under the curve","timeFrame":"Study Day 1 up to 65"},{"measure":"Half-life","timeFrame":"Study Day 1 up to 65"}],"references":[],"start_date":{"date":"2025-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06983743"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/auroras-1-nct06983743"}